Bluebird bio Inc. (NASDAQ:BLUE) stock dropped over 5% today, after the company announced interim data from an ongoing Starbeam study, which evaluates the use of Lenti-D product candidate in pediatric patients, who suffer from cerebral adrenoleukodystrophy (CALD). BLUE stock tumbled based on some safety issues highlighted in the data.
Starbeam study principal investigator David A. Williams commented: “CALD is a rare and deadly disease, and currently the only available treatment option is allogeneic hematopoietic stem cell transplant, which is often challenging for patients without a matched sibling donor.”
